Impact of national volume-based procurement reform on the markup of pharmaceutical firms: an event study

国家按量采购制度改革对制药企业加价的影响:一项事件研究

阅读:1

Abstract

BACKGROUND: In 2018, China’s National Healthcare Security Administration initiated a transformation of drug procurement towards national volume-based procurement (NVBP) of drugs, which disclosed the quantity information in the procurement auction, effectively reducing drug prices. We aim to theoretically and empirically shed light on the markup channel for the price effect, and explore the welfare effect of NVBP reform. METHODS: Based on the price discovery mechanism of reverse auction and the comparative analysis of the centralized procurement system before and after the reform, this study theoretically analyses the effect of the NVBP on pharmaceutical companies’ pricing strategies and the welfare consequences of the policy. Our theoretical model predicts reduced drug prices and increased procurement volume after the reform. We then empirically test these predictions by performing a difference-in-difference (DID) exercise on pharmaceutical firms’ markups and sales. RESULTS: The DID results show a significantly negative impact of NVBP on pharmaceutical firms’ markups (−0.0378, significant at 1%), a significantly negative effect of NVBP on markups for the chemical medicine producers with a larger scale of coefficient (−0.0411, significant at 1%), while a negative but insignificant coefficient for the other medicines (−0.0219). The results also show a significantly positive effect of NVBP on pharmaceutical companies’ sales (0.148, significant at 1%). CONCLUSIONS: The NVBP reform reduced the markups of pharmaceutical firms. The chemical medicines, which were highly exposure to the policy shock, were affected significantly, while the effect on the other types of medicines is weak. The NVBP reform also promoted the sales of medicines, and thus improved the social welfare. A further mechanical analysis shows that these results are mainly driven by a removal of market uncertainties, corruption, and transaction costs in the procurement process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12962-025-00664-2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。